Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Depression: Overview

Depression: Overview

Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...

Depressive Disorders: Etiology

Depressive Disorders: Etiology

Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...

Cognitive Therapy

Cognitive Therapy

Cognitive therapy, pioneered by Aaron T. Beck in the 1960s, is a structured approach to addressing psychological distress by focusing on the influence of thoughts on emotions and behaviors. All cognitive therapies involve the basic assumption that human beings have control over their feelings, and that how individuals feel about something depends on how they think about it. Unlike psychoanalytic methods that delve into unconscious processes or humanistic approaches emphasizing...

Antidepressant Drugs: Overview

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...

G-protein Coupled Receptors

G-protein Coupled Receptors

G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Quantifying the impact of immortal time bias: empirical evidence from meta-analyses.

Journal of the Royal Society of Medicine·2025

Same author

The efficacy and safety of anti-amyloid monoclonal antibody versus acetylcholinesterase inhibitor with an in-depth analysis across genotypes and disease stages: a systematic review and meta-analysis.

The journal of prevention of Alzheimer's disease·2025

Same author

The pharmacodynamics-based prophylactic benefits of GLP-1 receptor agonists and SGLT2 inhibitors on neurodegenerative diseases: evidence from a network meta-analysis.

BMC medicine·2025

Same author

The Efficacy and Acceptability of Non-Invasive Brain Stimulation Interventions for Obsessive-Compulsive Disorder Management: A Network Meta-Analysis Based on 24 Stimulation Methods.

Acta psychiatrica Scandinavica·2025

Same author

Tripeptides Featuring Dehydrophenylalanine and Homophenylalanine: Homo- Versus Hetero-Chirality and Sequence Effects on Self-Assembly and Gelation.

Gels (Basel, Switzerland)·2025

Same author

Haloperidol in treating delirium, reducing mortality, and preventing delirium occurrence: Bayesian and frequentist meta-analyses.

Critical care (London, England)·2025

Search research articles

Related Experiment Video

Updated: Apr 20, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Cognitive dysfunction in depression - pathophysiology and novel targets.

Andre F Carvalho, Kamilla K Miskowiak, Thomas N Hyphantis

¹Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceara, Rua Prof. Costa Mendes, 1608, 4o andar, 60430-040, Fortaleza, CE, Brazil. andrefc7@terra.com.br.

CNS & Neurological Disorders Drug Targets

|December 4, 2014

Summary

This summary is machine-generated.

Major depressive disorder (MDD) causes cognitive dysfunction that persists even in remission. This review synthesizes pathways and novel neurotherapeutics, like erythropoietin and SAMe, to improve cognitive function in MDD patients.

More Related Videos

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression

Published on: February 24, 2023

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

Related Experiment Videos

Last Updated: Apr 20, 2026

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression

Published on: February 24, 2023

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Author Spotlight: Unveiling the Connection Between Sleep Disorders and Cognitive Symptoms in Depression

Published on: April 26, 2024

Area of Science:

Neuroscience
Psychiatry
Pharmacology

Background:

Major depressive disorder (MDD) is linked to significant cognitive dysfunction affecting memory, executive function, processing speed, and attention.
These cognitive deficits persist in many patients even after remission, negatively impacting psychosocial functioning and work performance.
Current monoaminergic antidepressants offer limited efficacy for cognitive enhancement in MDD.

Purpose of the Study:

To review and synthesize the biological pathways implicated in cognitive dysfunction in MDD.
To identify and evaluate novel neurotherapeutic targets for cognitive enhancement in MDD patients.

Main Methods:

Comprehensive literature synthesis of studies on biological pathways contributing to cognitive deficits in MDD.
Review of preclinical and clinical evidence for novel neurotherapeutic agents targeting cognitive enhancement in MDD.

Main Results:

Identified interconnected biological pathways contributing to MDD cognitive dysfunction: hyperactive HPA axis, oxidative stress, inflammation, mitochondrial dysfunction, apoptosis, and reduced neurotrophic support.
Highlighted several promising neurotherapeutic targets including minocycline, statins, anti-inflammatory compounds, N-acetylcysteine, omega-3 fatty acids, erythropoietin, thiazolidinediones, GLP-1 analogues, SAMe, cocoa flavonols, creatine, and lithium.
Erythropoietin and SAMe demonstrated pro-cognitive effects in randomized controlled trials (RCTs) for MDD.

Conclusions:

Multiple biological pathways underlie cognitive dysfunction in MDD, suggesting complex pathophysiology.
While several novel agents show promise, further RCTs are essential to validate their efficacy for cognitive enhancement in MDD.
Targeting these pathways offers potential for developing more effective cognitive treatments for MDD.